window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P3V9EEXXWH');

dan@vitamindcreative.com

You Are Currently Here:Home > dan@vitamindcreative.com

About dan@vitamindcreative.com

This author has not yet filled in any details.
So far dan@vitamindcreative.com has created 5 blog entries.

CASE STUDY: See how Poseida Therapeutics is utilizing the “dual benefits” of our Nanoplasmid™ vector for success

Data from their ongoing Phase 1 expansion trial using Nanoplasmid demonstrated an improvement in efficacy over standard plasmid and a potentially best-in-class safety profile.

By |2021-01-15T16:55:46+00:00January 13th, 2021|CEO Corner|0 Comments

Cytovance Biologics offers Nature Technology Corporation’s proprietary HyperGRO™ manufacturing platform for plasmid DNA CGMP manufacturing

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial biologics and gene therapy plasmid DNA (pDNA), announces a new agreement with Nature Technology Corporation (NTC) for use of NTC’s proprietary HyperGRO™manufacturing platform.

By |2020-11-30T15:29:01+00:00November 30th, 2020|Press Release|0 Comments

Aegis Life and Entos will use NTC’s proprietary Nanoplasmid™ plasmid DNA technology and manufacturing platform for the clinical and commercial production of their SARS-CoV-2 vaccine

As part of a new agreement with Nature Technology Corporation (NTC), Aegis Life and Entos will use NTC's proprietary Nanoplasmid™ plasmid DNA technology and manufacturing platform for the clinical and commercial production of their SARS-CoV-2 vaccine...

By |2020-11-30T15:29:11+00:00October 15th, 2020|Press Release|0 Comments

Poseida Therapeutics utilizes Nanoplasmid® technology to demonstrate increased transposition frequency

Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure, today will present data related to its proprietary manufacturing process designed to optimize its CAR-T product candidates. The Company will also illustrate the impact of these optimizations with preclinical data and preliminary clinical analysis with a focus on P-BCMA-101, its autologous CAR-T product candidate for multiple myeloma. The findings will be presented today at CAR-TCR Digital Week 2020 being held September 14-17, 2020.

By |2020-11-30T15:29:25+00:00September 16th, 2020|Press Release|0 Comments

Deborah Moorad-Watts Appointed Chief Executive Officer

Nature Technology Corporation, a leading developer and provider of non-viral vectors, technologies and services for advancing gene and cell therapy and immunotherapy, announced today that Deborah Moorad-Watts, formerly Chief Business Officer, has been appointed Chief Executive Officer of the Company....

By |2020-11-30T15:29:35+00:00May 5th, 2020|Press Release|0 Comments
Go to Top